Dainippon Sumitomo Pharma
 |
|
| Public KK | |
| Traded as | : |
| Industry | Biotech & Pharmaceuticals |
| Predecessor |
|
| Founded | October 1, 2005 (merger of Dainippon Pharmaceutical & Sumitomo Pharmaceuticals) |
| Headquarters | 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka 541-0045, Japan |
|
Key people
|
Masayo Tada, (President and CEO) |
| Products |
|
| Revenue | (¥ 387.69 billion) (FY 2013) |
|
|
|
|
Number of employees
|
7,009 (consolidated) 4,291 (non-consolidated) (as of June 30, 2014) |
| Website | Official website |
|
Footnotes / references |
|
US$ 194.94 million (FY 2013)
Sumitomo Dainippon Pharma Co., Ltd. (大日本住友製薬株式会社 Dainippon Sumitomo Seiyaku Kabushiki-Gaisha?) is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.
The original Dainippon Pharmaceuticals (Dainippon Seiyaku) was established in 1885 by Nagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established by Ogata Kōan. It was set up as a wholly private company invested by a number of people in Tokyo and Osaka, with the land and buildings let by the government. Technical expertise for the enterprise was provided by Shibata Shokei and Nagai Nagayoshi, who were also among the first students trained abroad at government expense.
The company started its operation in 1885 with equipment imported from Germany. The main products were tincture and other similar drugs listed in the Japanese Pharmacopoeia. Among them was ephedrine, an anti-asthma drug invented by Nagai. In 1893, however, Nagai left the company and the business started to make a loss. in 1898 it was acquired by Osaka Seiyaku (Osaka Pharmaceutical).
...
Wikipedia